VTRNA2-1 and renal carcinoma: Yet, vtRNA2-1 has been also proposed as an OG in ovarian, thyroid, endometrial, cervical and renal cancer (Ahnet al., 2018;Huet al., 2017;Leeet al., 2016;Leiet al., 2017;Liet al., 2017;Yeganeh & Hernandez, 2020).